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Objectives. To determine if Chlamydia pneumoniae (C. pneu-
moniae) is more prevalent in atherosclerotic compared with
normal blood vessels of patients requiring redo and first time
coronary artery bypass graft surgery (CABG).
Background. Serological and pathological studies have associ-
ated atherosclerosis with C. pneumoniae infection. As atheroscle-
rosis is one of the causes of graft failure following CABG, then it
may be expected that the prevalence of the organism in failed
grafts and diseased native vessels should be greater than in the
new grafts.
Methods. Endarterectomy specimens and failed and new grafts
were collected from 49 patients with late graft failure. Endarter-
ectomy specimens and new grafts were also collected from nine
patients having first time CABG. The presence of C. pneumoniae
DNA was then checked for using a nested polymerase chain
reaction.
Results. The prevalence of C. pneumoniae DNA in failed venous
grafts (38.2%) was similar to that in endarterectomy specimens
from native coronary arteries (38.5%) and greater than that in
new saphenous vein grafts (11.8%). However, it was similar to that
in new internal mammary artery grafts (30.0%). Also, the interval
between surgery in redo patients was the same regardless of
whether C. pneumoniae was present or not.
Conclusions. Cross sectional studies cannot determine whether
C. pneumoniae is a cause of atherosclerosis since they do not show
whether infection precedes or follows its development. However,
our results suggest that the organism is not an important factor in
graft failure or atherosclerosis.
(J Am Coll Cardiol 1999;33:152–6)
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A serological association between antibodies to Chlamydia
pneumoniae (C. pneumoniae) and coronary artery disease was
first described in 1987 (1). This has been confirmed by many
(2–4), but not all, studies (5). Furthermore, DNA and antigen
detection methods such as the polymerase chain reaction
(PCR) and immunocytochemistry (ICC), as well as other
techniques such as electron microscopy and culture, have
found evidence for the presence of C. pneumoniae in athero-
sclerotic blood vessels (6–12). In a recent systematic review,
the organism was found in 52% of diseased but only 5% of
normal blood vessels (13). One possible explanation of these
serological and pathological findings is that C. pneumoniae has
a direct causal role in atherosclerosis. Atherosclerosis is one
cause of graft failure following coronary artery bypass graft
surgery (CABG) (14). In this study we hypothesized that if C.
pneumoniae causes atherosclerosis, then in patients with graft
failure, it should be more prevalent in failed grafts compared
with new saphenous vein (SV) and new internal mammary
artery (IMA) grafts. Also, all other things being equal, graft
failure should occur earlier in those patients with vascular C.
pneumoniae infection. Similarly, for patients requiring first
time CABG, C. pneumoniae should be more common in
diseased native coronary arteries compared with new grafts.
Methods
Forty-nine consecutive patients presenting for elective redo
(second) CABG were recruited between March 1996 and
January 1998 following approval from the local research ethics
committee. Another nine consecutive patients presenting for
first time CABG but who, in addition, had coronary endarter-
ectomy during their operation were also recruited. Demo-
graphic characteristics, smoking habits and medical history
were recorded from each patient. From redo patients, a
segment of one or more failed grafts was obtained. The
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decision as to whether or not to remove a failed graft and
which failed graft to remove was left to the clinical discretion
of the surgeon. From patients requiring first time CABG,
endarterectomy specimens from native coronary arteries that
were not grafted were obtained. In some cases, endarterec-
tomy specimens were also available from redo patients. From
all patients, we attempted to obtain surplus segments of newly
harvested saphenous vein and internal mammary artery grafts.
Vessel specimens (1 to 5 cms in length) were collected in the
sterile environment of the operating theatre and processed
immediately by dividing them into three portions, one for
histology, one for PCR and the final portion stored in liquid
nitrogen for future reference.
PCR. To prevent DNA contamination, different laborato-
ries were used for pre- and post-PCR handling. Dedicated
hoods, UV sterilization of equipment and filter pipette tips
were used. DNA was obtained from specimens using conven-
tional methods. Briefly, samples were digested with Proteinase
K followed by phenol chloroform extraction and ethanol-
sodium acetate precipitation. The DNA obtained was resus-
pended in 50 ml of purified water. To check for PCR inhibitors
in extracted DNA, 5 pg of lambda phage DNA was added to
3 ml of extracted DNA and subjected to PCR with lambda
specific primers (Table 1). Inhibitors were considered to be
present if there was no amplification, and extracted DNA was
then diluted by a factor of 10 and the PCR repeated. For
detection of C. pneumoniae DNA, a nested PCR with primer
sets from the C. pneumoniae omp 1 gene was used (15). A
positive control and one negative control for every five to six
samples were included in each experiment. PCR products were
visualized with ethidium bromide after electrophoresis on a
2% agarose gel. Polymerase chain reaction products were also
slot blotted and hybridised to a digoxigenin-deoxy-uridine
triphosphate labelled DNA probe consisting of a 242 bp VS4
fragment that spanned the target sequence. Hybridization
products were detected colorimetrically using nitro blue tetra-
zolium and X-Phosphate according to the manufacturer’s
instructions (Boehringer Mannheim, Lewes, United King-
dom). All C. pneumoniae PCRs were carried out in triplicate.
Statistical analysis. The x2 test was used to compare
proportions of categorical variables. The two sample t test (2
tailed, assuming equal variance) was used to compare contin-
uous variables from two populations. A significance level of
p 5 0.05 was used.
Results
Redo CABG patients. The characteristics of the 49 patients
who underwent redo CABG are shown in Table 2. The time
interval between CABG operations was at least six years for all
patients except for one (three years). Therefore, this repre-
sents a group of patients with late graft failure. We obtained at
least one failed vein graft from each of 47 patients. Of the
other two patients, an endarterectomy sample was available
from one, but no diseased vessel was available from the other.
Endarterectomy samples were available from three patients in
total. We obtained at least one new saphenous vein graft from
each of 41 patients. Of the other eight patients, new IMA
grafts were available for two, but no undiseased vessel was
available from six patients. New IMA grafts were available
Abbreviations and Acronyms
CABG 5 Coronary artery bypass graft surgery
ICC 5 immunocytochemistry
IMA 5 internal mammary artery
PCR 5 polymerase chain reaction
SV 5 saphenous vein
Table 1. PCR Primers and Reaction Conditions
PCR Target Primer Primer Sequence Product Size PCR Conditions
l phage DNA l1 59-ATG CAA TAT GCC ATT GCA GG-39 647 bp 30 cycles of 94°C for 40s, 48°C for 40s
and 72°C for 45sl2 59-TTA TAC CTC TGA ATC AAT ATC AAC-39
C. pneumoniae OMP1 gene
(round 1)
APNOU
APNOL
59-AAT TCT CTG TAA ACA AAC CC-39
59-ATT AAG AAG CTC TGA GCA TA-39
561 bp 30 cycles of 94°C for 30s, 52°C for 30s
and 72°C for 30s. Final extension cycle
of 72°C for 7 mins
C. pneumoniae OMP1 gene
(round 2)
APN1
APN2
59-TGC CAA CAG ACG CTG GCG-39
59-AGC CTA ACA TGT AGA CTC TGA T-39
488 bp 35 cycles of 94°C for 30s, 63°C for 30s
and 72°C for 30s. Final extension cycle
of 72°C for 7 mins
VS4 region of OMP1 gene T1APN4L 59-ATT TTA CGG AGA CTA TGT TT-39 242 bp 40 cycles of 94°C for 30s, 50°C for 30s
and 72°C for 45s.4APN10U 59-TAG TGC CAT ACA TTG GAG TA-39
Table 2. Vascular Risk Factors and Other Characteristics of
Patients Undergoing Redo CABG
Characteristic
C. pneumoniae
Positive
(n 5 19)
C. pneumoniae
Negative
(n 5 30) p value*
Age (years) 6 SD 67.1 6 5.9 66.2 6 6.5 0.66†
Male 18 (94.7%) 27 (90.0%) 0.56
Ex smoker‡ 11 (57.9%) 22 (73.3%) 0.26
Hypertension 6 (31.6%) 10 (33.3%) 0.90
Hyperlipidaemia 9 (47.4%) 18 (60.0%) 0.39
Time between first and
redo CABG (yrs)
12.8 6 5.9 12.6 6 3.4 0.89†
*x2 5 test unless otherwise indicated; † 5 two sample t test; ‡ 5 no patient
claimed to be a current smoker.
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from 15 patients in total. Eleven patients (22.4%) had C.
pneumoniae DNA in a failed graft or endarterectomy speci-
men only, two patients (4%) had C. pneumoniae in a new IMA
or SV graft only and five patients (10.2%) had C. pneumoniae
DNA in both failed and new grafts. The presence of C.
pneumoniae DNA was not associated with age, gender, smok-
ing, hypertension or hyperlipidaemia (Table 2), and the inter-
val between CABG operations was the same in patients with
and without C. pneumoniae DNA in their vessels.
First time CABG patients. Nine patients were recruited
with an average age of 70.4 6 9.2 years (4 males, 5 females). At
least one new SV graft and one endarterectomy specimen was
obtained from every patient but a new IMA graft was obtained
from only five patients. Four patients had an endarterectomy
specimen that was positive for C. pneumoniae, and, of these,
one also had a new IMA graft that was positive and another
had a new IMA and a new SV graft that was positive.
It can be seen from Table 3 that, in all patients, the
prevalence of C. pneumoniae in diseased vessels (failed grafts
and endarterectomy specimens) was similar to that in new
IMAs but greater than that in new SV grafts (p 5 0.001).
PCR inhibition. DNA samples extracted from atheroscle-
rotic vessels were more likely to show inhibition to PCR
compared with nonatherosclerotic vessels (29/68 vs. 19/71, P 5
0.05). However, on repeat PCR for C. pneumoniae, positive
atherosclerotic vessels were more likely to be positive on two
or more occasions than positive nonatherosclerotic vessels
(13/26 vs. 3/12) although this was not statistically significant.
This may be because the quantity of C. pneumoniae DNA is
greater in diseased vessels. Inhibition was eliminated in all
cases by tenfold dilution of the DNA sample. Although
dilution inevitably dilutes the amount of DNA, 14 of 48
inhibited samples (29.2%) were positive at least once com-
pared with 24 of 91 uninhibited samples (26.3%). Also, inhib-
ited samples were just as likely to be positive on two or more
occasions as uninhibited samples (7/14 vs. 9/24).
Discussion
Detection of C. pneumoniae in atherosclerotic vessels. The
most common methods for detecting C. pneumoniae in athero-
sclerotic vessels are PCR and antigen detection techniques
such as ICC. However, the specificity and sensitivity of these
methods are unknown. Ideally, infection by C. pneumoniae
should be confirmed by culture and the results of PCR and
ICC compared to this. Unfortunately, culture of C. pneu-
moniae from atherosclerotic vessels is technically difficult and
there have only been three reports of this. In the first study, C.
pneumoniae was cultured from a coronary artery and this was
confirmed by three of four laboratories using PCR and one of
two laboratories using ICC (9). In the second study, C.
pneumoniae was isolated from a carotid artery but both PCR
and ICC were negative (16). Finally, multiple serial passage
was used to isolate C. pneumoniae from 11 of 70 arteries and all
11 results were confirmed by PCR (7), but ICC was not used.
Therefore, there is insufficient data in the literature to assess
whether PCR or ICC is the most sensitive for detection of
vascular C. pneumoniae. Generally, ICC reports more positive
results than PCR (11,16), but this is not always the case (9,17).
The concern is that antibodies used in ICC may cross-react
with components of atherosclerotic tissue, and in some studies
results have depended on the antibody used. Genus-specific
antibodies against lipopolysaccharide have been reported to
give more positive results than species-specific antibodies
(18,19) and some species-specific antibodies appear to be more
sensitive than others (20). Furthermore, the results of these
different antibodies do not necessarily correlate with each
other. For example, a genus specific antibody found 79.8% of
114 samples to be positive for C. pneumoniae compared with
53.2% using a species-specific antibody, but the kappa statistic
was only 0.047 (18). We had intended to use ICC, but
preliminary studies failed to convince us of its specificity.
Background staining was also high, and other groups have
reported this (10). The advantage of PCR is that positive
results can be confirmed by sequencing of PCR products or by
Southern hybridization, but PCR also has disadvantages.
Atherosclerotic tissue has many inhibitors of PCR as has been
illustrated in this study. The DNA extraction process is impor-
tant, and techniques must achieve a balance between maximal
DNA extraction and removal of potential inhibitors. In a study
that compared different methods of extracting DNA from
atherosclerotic vessels, phenol chloroform extraction was
found to be superior to many commercial kits (21). We also
used dilution to eliminate inhibition and although this inevita-
bly results in DNA dilution, inhibited samples were just as
likely to be positive for C. pneumoniae as uninhibited samples.
All our specimens were tested in triplicate, and although most
were not positive on all occasions, we counted them as positive
because our negative controls were consistently negative. It is
likely that the inconsistent results were due to a combination of
small amounts of DNA and low sample volumes. Inconsistent
results have also been reported by other groups (9), but these
problems of reduced sensitivity do not detract from the fact
that we found a high prevalence of C. pneumoniae DNA in new
IMA grafts.
C. pneumoniae in arteries and veins. The main finding of
this study was that C. pneumoniae was more common in the
arterial circulation (including failed venous grafts) than in
saphenous veins, but it was not more common in atheroscle-
rotic vessels than in nonatherosclerotic IMAs. Another study
has now also reported that C. pneumoniae can be found in
IMAs (22). At first sight, this appears to contradict previous
Table 3. The Number of Vessels (Percentage) Positive for C.
pneumoniae DNA by PCR
Failed
Vein Grafts
Coronary
Endarterectomy
Specimens New SVGs
New IMA
Grafts
Redo CABG 21/55 (38.2%) 1/3 (33.3%) 5/42 (11.9%) 4/15 (26.7%)
First time CABG 4/10 (40.0%) 1/9 (11.1%) 2/5 (40%)
All patients 21/55 (38.2%) 5/13 (38.5%) 6/51 (11.8%) 6/20 (30.0%)
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studies. Thus, Muhlestein et al. (8) detected C. pneumoniae in
79% of atherectomy specimens compared with 4% of nonath-
erosclerotic coronary arteries. A study of young adult deaths
(11) reported similar findings. However, whereas these studies
have compared patients with and without atherosclerosis, we
have compared atherosclerotic and nonatherosclerotic blood
vessels from patients with atherosclerosis. Taken together,
these data may imply that C. pneumoniae is more common in
blood vessels of patients with atherosclerosis but that, in such
patients, it may be present in any artery including those which
are not normally subject to atherosclerosis. Thus, of the seven
redo patients in this study who had C. pneumoniae in a new
graft, five also had C. pneumoniae in a failed graft. Likewise,
both of the first time CABG patients who had C. pneumoniae
in a new graft also had an endarterectomy specimen that was
positive. In a post mortem study of C. pneumoniae in athero-
sclerotic coronary arteries (23), the organism was also detected
in noncardiovascular tissue (lung, liver and spleen), although
less frequently. However, the prevalence of the organism in
normal arteries and veins was not specifically addressed. It is
uncertain as to why the prevalence of C. pneumoniae is greater
in the arterial rather than the venous circulation. It has been
hypothesized that C. pneumoniae is primarily a cause of
respiratory infection and enters the circulation after being
ingested by alveolar macrophages. In this case, organisms will
enter the arterial circulation first after reaching the heart from
the lungs. We speculate that chlamydiae may effectively be
filtered out in the capillaries or alternatively, that haemody-
namic factors, such as higher blood pressure, are important in
making arteries more susceptible to colonization with C.
pneumoniae.
Graft failure. Generally, IMA grafts last substantially
longer than SV grafts as they are less prone to develop
atherosclerosis (14). However, we found that new IMA grafts
were more likely than new SV grafts to be infected with C.
pneumoniae (Table 3). Furthermore, redo patients whose
failed grafts were found to be infected with C. pneumoniae did
not present for their second operation any earlier than those
patients whose failed grafts were not infected (Table 2). Taken
together, these data suggest that C. pneumoniae is not an
important risk factor in graft failure. In this study, patients
undergoing redo or first time CABG were of similar age and
the prevalence of C. pneumoniae was also similar in both
groups. In contrast, in a study of patients undergoing direc-
tional atherectomy (12), it was reported that C. pneumoniae
was more likely to be found in restenotic compared with
primary lesions although this was not statistically significant.
However, whereas late graft failure is mainly due to athero-
sclerosis, the cause of restenosis following atherectomy is
incompletely understood (24). It was suggested that C. pneu-
moniae might be important in restenosis but another atherec-
tomy study found that the only clinical predictor of the
presence of C. pneumoniae was the presence of a primary
nonrestenotic lesion (8).
Native coronary atherosclerosis. Several processes contrib-
ute to vein graft failure including thrombosis in the early stages
and fibrointimal hyperplasia and graft atherosclerosis in the
later stages. Our patients were mainly those with late graft
failure requiring redo surgery. It could be argued that although
graft atherosclerosis has many similarities to native coronary
atherosclerosis there are differences (14); therefore, C. pneu-
moniae may still be important in native coronary atheroscle-
rosis. However, in the nine first time CABG patients, the
presence of C. pneumoniae DNA in endarterectomy specimens
was no greater than that in new IMA grafts. Also, there was a
high prevalence of C. pneumoniae in the IMA from all patients
and this is a vessel which is not prone to any form of
atherosclerosis.
In summary, in patients undergoing first time or redo
CABG, C. pneumoniae can be found in both atherosclerotic
and nonatherosclerotic arteries and, to a lesser extent, in new
saphenous vein grafts. This suggests that C. pneumoniae is not
important in causing late graft failure or disease of native
coronary arteries. However, cross sectional studies such as this
give no information on the temporal sequence of events. It is
not known whether C. pneumoniae infection preceded or
followed the development of atherosclerosis. It is possible that
if C. pneumoniae infects a preexisting lesion, it may cause
disease progression rather than initiate atherosclerosis itself.
Thus, in New Zealand White Rabbits fed a diet supplemented
with small amounts of cholesterol, intranasal inoculation with
C. pneumoniae was found to increase the size of atheromatous
aortic lesions and this could be prevented by azithromycin (25).
In two other studies using New Zealand White Rabbits fed
normal diets, intranasal inoculation resulted in aortic changes
consistent with atherosclerosis, but such changes were early
and compatible with arteritis (26,27). Aortic changes were not
seen in a fourth study (28). Two secondary prevention trials
have also suggested that C. pneumoniae may have a role in
atherosclerosis (29,30). Patients given macrolide antibiotics
were found to be at lower risk for further adverse cardiovas-
cular events and this benefit was seen as early as one month
(30) after onset of treatment. However, both studies were
small, with just over 200 patients each, and preliminary results
after six months of follow up from a third, similar sized study
have not shown any such benefit (31). A fourth study recruited
34 men who had previously had CABG and randomized them
to placebo or doxycycline for four months. No evidence of any
effect on forearm basal nitric oxide production or C. pneu-
moniae antibody titres was seen (32). It is evident that further
research, including larger antibiotic intervention trials, is re-
quired to determine if C. pneumoniae plays a significant
pathological role in atherosclerosis.
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